BIOMEDITECH ApS: Financial statements 2023
CVR: 34707847
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
BIOMEDITECH ApS (CVR 34707847) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 138,093 and a net result of DKK 186,499 compared with DKK 105,612 the year before. That is an increase of 22.9% compared with the year before. The profit margin was 135.1%. Equity in the 2023 report amounted to DKK 419,137. The solvency ratio was 89.1%.
- Revenue
- DKK 138,093
- Gross Profit
- DKK 138,023
- Profit/Loss
- DKK 186,499
- Equity
- DKK 419,137
- Total Assets
- DKK 470,540
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 138K | 138K | 186K | 419K | - |
| 2022 | 112K | 112K | 106K | 233K | - |
| 2021 | - | - | 76K | 127K | - |
| 2020 | 27K | 27K | 17K | 51K | - |
| 2019 | - | - | -13K | 34K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
BIOMEDITECH ApS has published its annual report for 2022. Revenue came to DKK 112,317, and the net result was DKK 105,612.
About BIOMEDITECH ApS
BIOMEDITECH ApS is a Danish company of the type Anpartsselskab based in Herlev, founded in 2012. The company is registered under the industry Engroshandel med andre maskiner og andet udstyr. The company was previously named DRUG TESTING EUROPE ApS. The management consists of Tobias Chalmer Stahl Rasmussen. The company is owned by Chalmer Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 106,895 and a net result of DKK -6,298 compared with DKK 290,046 the year before. Equity in the 2025 report amounted to DKK 877,884.